XPPen Unveils Stunning New Artist 12 3rd with X-Dial Shortcut Keys and Upgraded X4 Smart Chip Stylus
LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- XPPen today unveiled the groundbreaking Artist…
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha…
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”)…
Missed out on gold and Bitcoin? RWA is creating a new batch of multi-millionaires!
London, UK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- As global markets face…
From Economic Turbulence to a New Era of Wealth: NB HASH RWA Brings Real-World Assets On-Chain for Stable Digital Growth
London, UK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- As global markets face…
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platforms Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers…
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase…
ESR and Colt DCS Announce Joint Venture on New Osaka Data Centre Development
TOKYO, Oct. 16, 2025 /PRNewswire/ -- ESR, an Asia-Pacific ("APAC") focused real…
How leaming Chinese becomes a new trend in Fiji
GUANGZHOU, China, Oct. 16, 2025 /PRNewswire/ -- News report from GDToday: In…
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving…
